gammaCore Non-Invasive Vagus Nerve Stimulation (nVNS) Improves Neurobehavioral Outcomes in a Model of Traumatic Brain Injury
October 20, 2022 08:00 ET
|
electroCore, Inc.
ROCKAWAY, N.J., Oct. 20, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced data from an oral presentation at Neurocritical...
electroCore Provides Select Third Quarter 2022 Financial Guidance
October 14, 2022 16:01 ET
|
electroCore, Inc.
ROCKAWAY, N.J., Oct. 14, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”) (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today provided select unaudited preliminary...
electroCore Strengthens Patent Portfolio with Issuance of Four New U.S. Patents
September 21, 2022 08:00 ET
|
electroCore, Inc.
ROCKAWAY, N.J., Sept. 21, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that the United States Patent and Trademark...
Electrocore Announces Date for Fiscal Year 2022 Annual Meeting and Deadlines for Stockholder Proposals
September 20, 2022 08:00 ET
|
electroCore, Inc.
ROCKAWAY, N.J., Sept. 20, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR) (the “Company”), a commercial-stage bioelectronic medicine company, today announced its plans to hold its fiscal...
gammaCore (Non-Invasive Vagus Nerve Stimulation; nVNS) Reduces Symptoms of Acute Withdrawal in Patients with Opioid Use Disorder
September 07, 2022 08:00 ET
|
electroCore, Inc.
ROCKAWAY, N.J., Sept. 07, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced the publication of a peer reviewed...
electroCore to Participate at Upcoming Investor Conferences
September 06, 2022 08:00 ET
|
electroCore, Inc.
ROCKAWAY, N.J., Sept. 06, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that electroCore’s Chief Executive Officer,...
electroCore to Participate at Canaccord Genuity 42nd Annual Growth Conference
August 05, 2022 08:00 ET
|
electroCore, Inc.
ROCKAWAY, N.J., Aug. 05, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that electroCore’s Chief Executive Officer, Dan...
electroCore Announces Record Second Quarter 2022 Financial Results
August 04, 2022 16:05 ET
|
electroCore, Inc.
Record second quarter 2022 net sales of $2.2 million, increased 70% over second quarter 2021 and 14% sequentially Company to host a conference call and webcast today, August 4, 2022 at 4:30 pm EDT ...
electroCore to Announce Second Quarter 2022 Financial Results on August 4
July 28, 2022 08:00 ET
|
electroCore, Inc.
ROCKAWAY, N.J., July 28, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today that it will report financial results for the...
electroCore Provides Select Second Quarter 2022 Financial Guidance
July 12, 2022 08:00 ET
|
electroCore, Inc.
Record revenue will be at least $2.1 million; approximately 65% growth over second quarter 2021June 30, 2022, cash and cash equivalents balance of approximately $26.6 million ROCKAWAY, N.J., July ...